Shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) were up 14% during mid-day trading on Friday . The stock traded as high as $0.51 and last traded at $0.49. Approximately 1,049,643 shares were traded during trading, an increase of 58% from the average daily volume of 663,791 shares. The stock had previously closed at $0.43.
Several analysts recently issued reports on PLX shares. Zacks Investment Research lowered Protalix Biotherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 9th. HC Wainwright set a $4.00 target price on Protalix Biotherapeutics and gave the stock a “buy” rating in a report on Thursday, December 13th.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLX. Virtu Financial LLC raised its holdings in Protalix Biotherapeutics by 44.4% during the fourth quarter. Virtu Financial LLC now owns 91,862 shares of the company’s stock worth $29,000 after acquiring an additional 28,236 shares in the last quarter. Fosun International Ltd bought a new stake in Protalix Biotherapeutics during the third quarter worth about $1,881,000. Finally, Renaissance Technologies LLC raised its holdings in Protalix Biotherapeutics by 24.9% during the third quarter. Renaissance Technologies LLC now owns 3,266,401 shares of the company’s stock worth $2,374,000 after acquiring an additional 651,701 shares in the last quarter.
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Recommended Story: What is dollar cost averaging (DCA)?
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.